Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations (Q38181692)

30 August 2017

Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations (English)

1 reference

chronic obstructive pulmonary disease

30 August 2017

1 reference

Peter M A Calverley

1

1 reference

PubMed ID

24461617

30 August 2017

Paul Albert

series ordinal

2

1 reference

PubMed ID

24461617

30 August 2017

Paul P Walker

series ordinal

3

1 reference

30 August 2017

18 June 2013

1 reference

The Lancet. Respiratory medicine

30 August 2017

1 reference

30 August 2017

1

1 reference

30 August 2017

564-573

1 reference

30 August 2017

7

1 reference

Small-airway obstruction and emphysema in chronic obstructive pulmonary disease

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Pathophysiology of airflow limitation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

The natural history of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Acute bronchodilator trials in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Bronchodilator reversibility in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Impact of bronchodilator use on the prevalence of COPD in population-based samples

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Spirometry in the Lung Health Study: II. Determinants of short-term intraindividual variability

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

FEV1 response to bronchodilation in an adult urban population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Interpretative strategies for lung function tests

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease. A clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Standardisation of spirometry

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Prognosis in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Changes in forced expiratory volume in 1 second over time in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Bronchodilator response in the lung health study over 11 yrs.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Bronchodilator responsiveness in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Prevalence and clinical correlates of bronchoreversibility in severe emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Use of respiratory medication in five Latin American cities: The PLATINO study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

A PEACE-ful solution to COPD exacerbations?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

A simple method to detect expiratory flow limitation during spontaneous breathing

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Evolution of Dyspnea during Exercise in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Assessment of emphysema in COPD: a functional and radiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Severity of airflow limitation is associated with severity of airway inflammation in smokers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Evasion of COPD in smokers: at what price?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Risk of severe asthma episodes predicted from fluctuation analysis of airway function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Mast-cell infiltration of airway smooth muscle in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970086-9

7 January 2021

10.1016/S2213-2600(13)70086-9

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24461617